PDL BioPharma, Inc. EBITDA

EBITDA of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.


Highlights and Quick Summary

  • EBITDA for the quarter ending June 29, 2020 was $-12.7 Million (a -58.53% decrease compared to previous quarter)
  • Year-over-year quarterly EBITDA decreased by -176.4%
  • Annual EBITDA for 2019 was $-82.4 Million (a 251.29% increase from previous year)
  • Annual EBITDA for 2018 was $-23.5 Million (a -110.12% decrease from previous year)
  • Annual EBITDA for 2017 was $232 Million (a 53.09% increase from previous year)
  • Twelve month EBITDA ending June 29, 2020 was $-115 Million (a 6.12% increase compared to previous quarter)
  • Twelve month trailing EBITDA decreased by -365.85% year-over-year
Trailing EBITDA for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-115 Million $-108 Million $-82.4 Million $43.1 Million
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of PDL BioPharma, Inc.

Most recent EBITDAof PDLI including historical data for past 10 years.

Interactive Chart of EBITDA of PDL BioPharma, Inc.

PDL BioPharma, Inc. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-12.68 $-30.57
2019 $-87.93 $16.59 $-6.07 $-5.0 $-82.41
2018 $37.58 $41.19 $-115.94 $13.72 $-23.46
2017 $39.86 $42.58 $122.17 $27.26 $231.87
2016 $2.29 $40.72 $12.7 $95.75 $151.46
2015 $164.76 $118.71 $133.79 $146.12 $563.38
2014 $104.58 $162.76 $160.53 $136.99 $564.87
2013 $111.21 $95.48 $144.77 $87.96 $439.42
2012 $88.01 $83.09 $124.6 $74.37 $370.06
2011 $70.94 $83.44 $120.74 $79.91 $355.03
2010 $-26.14 $77.57 $113.83 $220.33

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.